Featured publications
Featured publications
Embedded Files
Cited 251 times (expand list for full bibliography).
Cited 251 times (expand list for full bibliography).
Shaya, J., Pettit, K., Kandarpa, M., Boonstra, P.S., Mercer, J., Talpaz, M. Late responses in patients with Chronic Myeloid leukemia initially refractory to tyrosine kinase inhibitors. Clinical Lymphoma, Myeloma, and Leukemia. 2022 Jan;22(1):17-23.
Garmezy, B., Schaefer, J.K., Mercer, J., Talpaz, M. A Provider’s Guide to Primary Myelofibrosis: Pathophysiology, Diagnosis, and Management. Blood Reviews. 2021. Jan;45:100691.
Girard, J., Mercer, J., and Phillips, T., Evaluating acalabrutinib in the treatment of mantle cell lymphoma: design, development and place in therapy. OncoTargets and Therapy. 2019. Sep 30;12:8003-8014.
Phillips, T. and J. Mercer. Surveillance Scans in Lymphoma: Friend or Foe? Curr Treat Options Oncol. 2017. 18(2):10.
Talpaz, M., Hehlmann, R., Quintás-Cardama, A., Mercer, J., Cortes, J. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. Leukemia, 2013. 27(4): p. 803-812.
Menghrajani K., Boonstra P.S., Mercer J.A., Perkins C, Gowin KL, Weber AA, Mesa R, Gotlib JR, Wang L, Singer JW, Talpaz M. Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leuk Lymphoma. 2019. Apr;60(4):1036-1042.
Peterson, L., Lo, M., Lui, Y., Gianolla, D., Mitrikeska, E., Donato, N., Johnson, C., Wang, S., Mercer, J. and Talpaz, M. Induction of p53 suppresses chronic phase myeloid leukemia stem cells. Leuk Lymphoma. 2017. 58(9):1-14.
Talpaz, M., Mercer, J. and Hehlmann, R. The interferon-alpha revival in CML. Annals of Hematology, 2015. 94(Suppl 2): p. 195-207. Phillips, T., Mercer, J. and Talpaz, M. The lymphoma misfit: a review of mantle cell lymphoma. Trends in Cancer Research, 2014. 10: p. 45-61.
Fields, J., Gardner-Mercer, J., Borgmann, K., Clark, I. and Ghorpade, A. CCAAT/enhancer binding protein β expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1. J Neurochem, 2011. 118(1): p. 93-103.
Gardner, J., Borgmann, K., Deshpande, M., Dhar, A., Wu, L., Persidsky, R. and Ghorpade, A. Potential mechanisms for astrocyte-TIMP-1 downregulation in chronic inflammatory diseases. J Neurosci Res, 2006. 83(7): p. 1281-92.
Dhar, A., Gardner, J., Borgmann, K., Wu, L. and Ghorpade, A. A novel role of TGF-β in differential astrocyte-TIMP-1 regulation: Implications for HIV-1-dementia and neuroinflammation. J Neurosci Res, 2006. 83(7): p. 1271-80.
Gardner, J. and Ghorpade, A. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res, 2003. 74(6): p. 801-6.
Featured grant proposals
Featured grant proposals
D. Dan and Betty Kahn Foundation Award – UM Bone Marrow Failure Research Program, 2014-2021, $2,316,596
NCI R01 – Targeted Elimination of Cancer Stem Cells for AML Therapy, 2013-2018, $2,395,975
NCI K08 – The role of GATA-3 in T-cell lymphomas, 2013-2017, $893,090
Sanofi Adventis - Identifying Molecular Characteristics of Myelofibrosis Patients, 2013-2015, $736,434
Marvin and Betty Danto Family Foundation Award — Developing a New Drug for Multiple Myeloma, 2013-2015, $281,025
Brystol-Myers Squib Award – Effects of JAK-2 Inhibitor (BMS-911543) Combined with Dasatinib on CML Primitive Progenitors, 2013-2014, $50,000
Therapeutic Acceleration Program of the Leukemia Lymphoma Society – DUB Inhibitors for Treatment of B-cell Malignancies, 2012-2014, $332,997
NIH R01: A non-active site-directed approach to inhibit deubiquitinases for cancer therapy, June 2015
DOD Medical Research Program: Targeting the deubiquitinase pathway for myelodysplastic syndromes therapy April 2015
Israel Cancer Research Fund: Targeting STAT3 in Hematological Malignancies, Jan 2015
NIH R21: Inhibition of JAK2 as a Therapeutic Strategy to Target Leukemia Stem Cells in Chronic Myeloid Leukemia May 2014
Sanofi: Inhibition of JAK2 as a Therapeutic Strategy to Target Leukemia Stem Cells in Chronic Myeloid Leukemia Jan 2014
NIH Loan Repayment Program: Phase I dose escalation study to determine the maximum tolerated dose of the combination of and Velcade in patients with relapsed or refractory lymphoma, Sept 2013
NIH UM1: Michigan-Indiana Network for Experimental Therapeutics August 2013
Page updated
Google Sites
Report abuse